NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Liid Pharmaceuticals, Inc.

Liid Pharmaceuticals, Inc.

Private
SuitaHealthcare & Life Scienceshttps://liidpharma.co.jp/

Last Round

Grant

Jan 13, 2026

Est. Valuation

$7.89M

Total Funding Raised

$2.73M

Company Overview

Liid Pharmaceuticals, Inc. is a biotechnology company that develops antisense oligonucleotide therapeutics using its proprietary BROTHERS technology platform to treat intractable diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

antisense oligonucleotideASOnucleic acid therapeuticspeptide nucleic acidPNAdrug discovery platformbiotech startupchemistry manufacturing and controlsCMCdrug delivery technologyligand conjugationintractable disease treatmentpharmacokinetic profilingPK/PDlipid metabolism

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Liid Pharmaceuticals, Inc. Comparables

Compare Liid Pharmaceuticals, Inc. with similar companies based on industry and business-model similarity.

Liid Pharmaceuticals, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rena Therapeutics Inc.
83%
Luxna Biotech Co., Ltd.
81%
TKG Therapeutics, Inc.
78%

Liid Pharmaceuticals, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 13, 2026
VC RoundApr 26, 2024
SeedOct 26, 2022

Key People

Founding team and executive leadership

Fumito Wada

Co-founder, President & CEO

Founding Team

Liid Pharmaceuticals, Inc. Investors

Notable investors and investment history

Liid Pharmaceuticals, Inc. investors
InvestorRounds
New Energy and Industrial Technology Development OrganizationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 5, 2025

    Grew 700% QoQ, from 1 to 8 employees.

Liid Pharmaceuticals, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Liid Pharmaceuticals, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Liid Pharmaceuticals, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSuita
Employee Range11
Year Founded2019
Last FundingJan 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.